Microcap Ledger Cartesian Therapeutics, Inc. $RNAC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Frederick, MD
- Fiscal year end
- December 31
- Shares outstanding
- 30,255,352 [10-Q 2026-08-06]
What the company doesAI summary of filing
Cartesian Therapeutics is a late clinical-stage biotechnology company developing cell therapies for autoimmune diseases. The company's lead product candidate, Descartes-08, is an autologous CAR-T cell therapy that uses mRNA to modify patients' cells; it is currently in Phase 3 trials for myasthenia gravis and Phase 2 trials for myositis and juvenile dermatomyositis, with a previous Phase 2 trial in systemic lupus erythematosus now discontinued. Descartes-08 is designed to be administered as outpatient infusions without requiring preconditioning chemotherapy, differentiating it from conventional DNA-based CAR-T therapies. The company manufactures its therapies in-house at a facility in Frederick, Maryland, and generates no revenue from product sales; it is pre-revenue and expects to incur losses as it advances its clinical programs. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $78.0K | −$23.41M | −$43.22M | $147.61M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $2.80M | −$130.30M | −$73.94M | $125.14M | [10-K 2026-03-09] |
| FY ended Dec 2024 | $38.91M | −$77.42M | −$23.67M | $212.61M | [10-K 2026-03-09] |
- Quarterly cash burn
- −$21.61M
- Cash runway Estimate
- ~20.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 25,414,898 | [10-Q 2024-11-07] |
| 2025-02-28 | 25,907,101 | [10-K 2025-03-13] |
| 2025-04-30 | 25,954,291 | [10-Q 2025-05-08] |
| 2025-08-01 | 26,002,042 | [10-Q 2025-08-07] |
| 2025-10-31 | 26,003,606 | [10-Q 2025-11-06] |
| 2026-02-28 | 26,509,024 | [10-K 2026-03-09] |
| 2026-04-23 | 29,381,514 | [10-Q 2026-04-30] |
| 2026-07-31 | 30,255,352 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2024-12-13; declared effective 2025-01-08 [S-3 2024-12-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-02 | Hoge Elizabeth | exercise | 758,001 | — | [4 2026-04-06] |
| 2026-04-02 | Kalayoglu Murat | exercise | 758,001 | — | [4 2026-04-06] |
| 2026-03-13 | Singer Michael | other | 6,555 | — | [4 2026-03-13] |
| 2026-01-06 | Brunn Carsten | sell | 23,766 | $6.82 | [4 2026-01-08] |
| 2026-01-06 | Miljkovic Milos | sell | 3,573 | $6.82 | [4 2026-01-08] |
| 2026-01-06 | Davis Blaine | sell | 10,591 | $6.82 | [4 2026-01-08] |
| 2026-01-02 | Desilva Nishan M | grant | 2,600 | — | [4 2026-01-06] |
| 2026-01-02 | Brunn Carsten | grant | 143,200 | — | [4 2026-01-06] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-13 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-22 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-17 | 8-K | Shareholder vote results |
| 2026-06-09 | 8-K | Regulation FD disclosure |
| 2026-05-26 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-05-06 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-30 | 10-Q | Quarterly report |
| 2026-04-30 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
Alerts for $RNAC
Email me when Cartesian Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.